Abstract

Sarcomas of bone are a rare and diverse set of tumors that, although related in their primary location (bone), vary in their etiology, behavior, and treatment. In 2011, approximately 2,890 new cases of bone and joint cancers were diagnosed in the USA. Osteosarcoma, chondrosarcoma, and Ewing sarcoma are the most common primary tumors of bone, representing 30 %, 15 %, and 6 %, respectively, of all bone sarcomas. The remainder of bone sarcomas is made up of malignant fibrous histiocytoma, chordoma, adamantinoma, hemangioendothelioma, hemangiopericytoma, and low-grade fibrosarcoma of the bone.

Keywords

Sarcoma Doxorubicin Methotrexate Cyclophosphamide Etoposide 

References

  1. 1.
    Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 2009;91:1063–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Smith MA, GJ, Ries LA. Cancer in adolescents 15 to 19 years old. In: Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1997 (NIH Pub. No. 99-4649). Bethesda, MD: National Cancer Institute; 1999.Google Scholar
  3. 3.
    Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2124–35.PubMedCrossRefGoogle Scholar
  4. 4.
    Ries LAG, SM, Gurney JG, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995 (NIH Pub. No. 99-4649). Bethesda, MD: National Cancer Institute; 1999. p. 99–110.Google Scholar
  5. 5.
    Data from the American Cancer Society. American Cancer Society. http://www.cancer.org/docroot/home/index.asp. Accessed 23 May 2012.
  6. 6.
    Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9–24.PubMedGoogle Scholar
  8. 8.
    Benjamin R, Chawla S, Murray J, et al. Preoperative chemotherapy for osteosarcoma: a treatment approach facilitating limb salvage with major prognostic indications. In: Jones S, Salmon S, editors. Adjuvant therapy of cancer IV. Philadelphia: Grune and Stratton; 1984. p. 601–10.Google Scholar
  9. 9.
    Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988–97.PubMedGoogle Scholar
  10. 10.
    Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5:21–6.PubMedGoogle Scholar
  12. 12.
    Rosen G, Nirenberg A. Neoadjuvant chemotherapy for osteogenic sarcoma: a five year follow-up (T-10) and preliminary report of new studies (T-12). Prog Clin Biol Res. 1985;201:39–51.PubMedGoogle Scholar
  13. 13.
    Mavligit GM, Calvo 3rd DB, Patt YZ, Hersh EM. Immune restoration and/or augmentation of local xenogeneic graft versus host reaction by Cimetidine in vitro. J Immunol. 1981;126:2272–4.PubMedGoogle Scholar
  14. 14.
    Stewart DJ, Benjamin RS, Zimmerman S, et al. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res. 1983;43:917–20.PubMedGoogle Scholar
  15. 15.
    Jaffe N, Raymond AK, Ayala A, et al. Effect of cumulative courses of intraarterial cis-diamminedichloroplatin-II on the primary tumor in osteosarcoma. Cancer. 1989;63:63–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Jaffe N, Robertson R, Ayala A, et al. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol. 1985;3:1101–4.PubMedGoogle Scholar
  17. 17.
    Bacci G, Ferrari S, Donati D, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. Oncol Rep. 1998;5:1259–63.PubMedGoogle Scholar
  18. 18.
    Jaffe N, Carrasco H, Raymond K, Ayala A, Eftekhari F. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer. 2002;95:2202–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Peabody TD, Gibbs Jr CP, Simon MA. Evaluation and staging of musculoskeletal neoplasms. J Bone Joint Surg Am. 1998;80:1204–18.PubMedGoogle Scholar
  20. 20.
    Link M, Meyers P, Gebhardt M. Osteosarcoma. In: Pizzo P, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott, Williams, & Wilkins; 2006. p. 1074–115.Google Scholar
  21. 21.
    Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:633–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Glass AG, Fraumeni Jr JF. Epidemiology of bone cancer in children. J Natl Cancer Inst. 1970;44:187–99.PubMedGoogle Scholar
  23. 23.
    Fraumeni Jr JF, Glass AG. Rarity of Ewing’s sarcoma among U.S. Negro children. Lancet. 1970;1:366–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer. 1993;53:371–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer. 2009;115:3526–36.PubMedCrossRefGoogle Scholar
  26. 26.
    Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000;18:4–11.PubMedGoogle Scholar
  27. 27.
    Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18:3108–14.PubMedGoogle Scholar
  28. 28.
    Nesbit Jr ME, Gehan EA, Burgert Jr EO, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990;8:1664–74.PubMedGoogle Scholar
  29. 29.
    Burgert Jr EO, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol. 1990;8:1514–24.PubMedGoogle Scholar
  30. 30.
    Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694–701.PubMedCrossRefGoogle Scholar
  31. 31.
    Ferrari S, Mercuri M, Rosito P, et al. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing’s sarcoma of the extremity. J Chemother. 1998;10:484–91.PubMedGoogle Scholar
  32. 32.
    Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol. 2003;21:3423–30.PubMedCrossRefGoogle Scholar
  33. 33.
    Gibbs CP, Weber KL, Scarborough MT. Malignant bone tumors. In: Beaty JH, editor. AAOS instructional course lectures, vol. 51. Rosemont: American Academy of Orthopaedic Surgeons; 2002. p. 413–28.Google Scholar
  34. 34.
    Bacci G, Toni A, Avella M, et al. Long-term results in 144 localized Ewing’s sarcoma patients treated with combined therapy. Cancer. 1989;63:1477–86.PubMedCrossRefGoogle Scholar
  35. 35.
    Wilkins RM, Pritchard DJ, Burgert Jr EO, Unni KK. Ewing’s sarcoma of bone. Experience with 140 patients. Cancer. 1986;58:2551–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Horowitz ME, Neff JR, Kun LE. Ewing’s sarcoma. Radiotherapy versus surgery for local control. Pediatr Clin North Am. 1991;38:365–80.PubMedGoogle Scholar
  37. 37.
    Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol. 2007;96:118–23.PubMedCrossRefGoogle Scholar
  38. 38.
    Wittig JC, Bickels J, Kellar-Graney KL, Kim FH, Malawer MM. Osteosarcoma of the proximal humerus: long-term results with limb-sparing surgery. Clin Orthop Relat Res. 2002;156–76Google Scholar
  39. 39.
    Lindner NJ, Ramm O, Hillmann A, et al. Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin Orthop Relat Res. 1999;83–9Google Scholar
  40. 40.
    Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994;12:2699–705.PubMedGoogle Scholar
  41. 41.
    Rougraff BT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am. 1994;76:649–56.PubMedGoogle Scholar
  42. 42.
    Nagarajan R, Clohisy DR, Neglia JP, et al. Function and quality-of-life of survivors of pelvic and lower extremity osteosarcoma and Ewing’s sarcoma: the Childhood Cancer Survivor Study. Br J Cancer. 2004;91:1858–65.PubMedCrossRefGoogle Scholar
  43. 43.
    Barr RD, Wunder JS. Bone and soft tissue sarcomas are often curable–but at what cost?: a call to arms (and legs). Cancer. 2009;115:4046–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Orthopaedic OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations